IRF3 and neoplasm: A recent study found that DNA damage response (DDR) inhibitors are sufficient to induce an anti-tumor immune response in small cell lung cancer, which is mediated by the STING-TANK binding kinase 1 (TBK1)-IFN regulatory factor 3 (IRF3) pathway13.